Legend Biotech Corporation (LEGN)
| Previous close | 50.83 |
| Open | 51.04 |
| Bid | 48.85 x 100 |
| Ask | 49.11 x 100 |
| Day's range | 48.31 - 51.32 |
| 52-week range | 38.60 - 70.78 |
| Volume | |
| Avg. volume | 906,923 |
| Market cap | 8.983B |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings date | 18 Nov 2024 - 22 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 82.99 |
Insider MonkeyLegend Biotech Corporation (LEGN): Among Hedge Funds’ Top Biotech Stock Picks
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against the other biotech stocks. The ability to successfully make money through investment requires deep thinking and analysis. Even then, it’s not […]
Insider MonkeyHere’s Why TimesSquare Capital Management U.S. Focus Growth Strategy Removed Legend Biotech Corporation (LEGN) from its Portfolio
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy returned 0.08% (gross) and -0.13% (net) compared to -3.21% for the Russell Midcap Growth Index. The equity markets performed well in the second […]
GuruFocus.comMatthews Emerging Markets Small Companies Fund Boosts Stake in Legend Biotech Corp
Insightful Portfolio Adjustments in Q2 2024 Highlight Strategic Moves
